Table 2.

Phenotype of circulating cytokeratin + cells

Patients	Cytokeratin %	EpCam %	Oct4a %	TET2%	5hmC %	CSC Support	Treatment
1	.85	.085	.09	Not Done	Not Done	Yes	Yes
2	5.92	.03	.02	.2	4.81	No	No
3	.24	.04	.04	0	.23	Possible	Yes
4	.79	.62	.76	0	0	Yes	Yes
5	9	.51	.67	.39	0	Yes	Yes
6	15.1	.39	6.3	.1	0	Yes	Yes
7	.46	.01	.26	0	0	Yes	Yes
8	.89	.79	.27	0	.85	No	Yes

Cytokeratin + cells were analyzed by gating the nucleated fraction in peripheral blood. The identified cytokeratin+ cells were further analyzed for the shown markers. CSC support was determined by analyses of the combined phenotype - EpCam and Oct4a as potential stemness, and further sustenance of CSCs with decreases in TET2 and/or 5hmC, which prevent demethylation